Maintaining Cost Efficiency In A Personalized Oncology World
Source: Bioprocess Online
To ensure patient access, development and manufacturing cost efficiency can’t be lost to the promise of personalized cancer vaccines. In this segment of the Bioprocess Online Live event, guest experts Peter Berglund, chief scientific officer at HDT Bio, Johanna Kaufmann, EVP for oncology at Codagenix, and Robert Georgantas, president and CTO at Providence Therapeutics weigh in on managing development and manufacturing costs.
access the Video!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.
Subscribe to Bioprocess Online
X
Subscribe to Bioprocess Online
This website uses cookies to ensure you get the best experience on our website. Learn more